Design Therapeutics, Inc. (DSGN)
| Market Cap | 789.15M +129.0% |
| Revenue (ttm) | n/a |
| Net Income | -70.80M |
| EPS | -1.18 |
| Shares Out | 62.58M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 528,369 |
| Open | 13.07 |
| Previous Close | 13.16 |
| Day's Range | 12.12 - 13.25 |
| 52-Week Range | 5.28 - 17.25 |
| Beta | 1.66 |
| Analysts | Strong Buy |
| Price Target | 21.00 (+66.53%) |
| Est. Earnings | Nov 4, 2026 |
About DSGN
Design Therapeutics, Inc. a clinical-stage biopharmaceutical company, research, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ sys... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for DSGN stock is "Strong Buy." The 12-month stock price target is $21.0, which is an increase of 66.53% from the latest price.
News
Design Therapeutics Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
Lead program DT-216 for Friedreich ataxia showed strong biomarker and functional improvements, with a 12-week efficacy readout expected in Q1 2027 and ongoing FDA engagement on surrogate endpoints. The DM1 program, DT-818, is advancing with a novel DNA-targeting mechanism and aims for a 2027 clinical readout.
Design Therapeutics management to meet with Oppenheimer
Meeting to be held on September 9 hosted by Oppenheimer.
Design Therapeutics to Participate in 2026 Cantor Fitzgerald Global Healthcare Conference
CARLSBAD, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, t...
Design Therapeutics reports Q2 EPS (32c), consensus (34c)
“Design continued its strong operational execution in the second quarter building on the positive RESTORE-FA data reported in May. Those four-week data demonstrated the ability of DT-216P2 to increase...
Design Therapeutics Provides RESTORE-FA Clinical Development Update and Reports Second Quarter 2026 Financial Results
RESTORE-FA trial modifications build on positive four-week data; expect to share data based on 12 weeks of dosing in the first quarter of 2027 Patient dosing initiated in Phase 1 multiple-ascending d...
Design Therapeutics Quarterly report: Q2 2026
Design Therapeutics has published its Q2 2026 quarterly earnings report on August 3, 2026.
Design Therapeutics Earnings release: Q2 2026
Design Therapeutics released its Q2 2026 earnings on August 3, 2026, summarizing the period's financial results.
Design Therapeutics initiates patient dosing in DT-818 trial
Design Therapeutics (DSGN) announced the initiation of patient dosing in its Phase 1 multiple-ascending dose clinical trial evaluating DT-818 in adults with myotonic dystrophy type-1. DT-818 is a Gene...
Design Therapeutics Announces Initiation of Patient Dosing in Phase 1 Multiple Ascending Dose Trial of DT-818 for Myotonic Dystrophy Type-1
GeneTAC ® small molecule designed to selectively reduce transcription of the mutant DMPK allele and address the underlying cause of DM1 CARLSBAD, Calif., June 30, 2026 (GLOBE NEWSWIRE) -- Design Thera...
Design Therapeutics Transcript: Jefferies Global Healthcare Conference 2026
A novel small molecule genomic medicine platform showed early clinical proof-of-concept in Friedreich's ataxia, with significant biomarker and clinical improvements at 1 mg/kg. Ongoing studies are being considered for registrational development, with a major update expected in Q4.
Design Therapeutics Slides: Corporate presentation
Design Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on June 1, 2026.
Design Therapeutics to Participate in 2026 Jefferies Global Healthcare Conference
CARLSBAD, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, tod...
Design Therapeutics Transcript: Status update
Four-week RESTORE-FA data show DT-216 is well-tolerated and delivers significant, dose-dependent increases in frataxin mRNA and protein, with robust clinical improvements in mFARS, upright stability, and fatigue. A registration path is being planned, with updates expected in Q4.
Design Therapeutics Press release: Status update
Design Therapeutics issued a press release on May 18, 2026, disclosing material business information to investors.
Design Therapeutics Slides: Status update
Design Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on May 18, 2026.
Design Therapeutics announces biomarker, clinical data from RESTORE-FA trial
Design Therapeutics (DSGN) announced biomarker and clinical data from the ongoing Phase 1/2 RESTORE-FA trial evaluating DT-216P2 in patients with Friedreich ataxia. DT-216P2 is a GeneTAC small-molecul...
Design Therapeutics Announces Four-Week IV Data from the RESTORE-FA Trial of DT-216P2 Demonstrating Clinical Improvements and Comprehensive Biomarker Activity in Friedreich Ataxia
DT-216P2 demonstrated dose-dependent improvement in multiple clinical measures and increases in endogenous frataxin mRNA and protein after four weeks of intravenous dosing
Design Therapeutics to Host Investor Webcast to Review Data from RESTORE-FA Trial of DT-216P2 for Friedreich's Ataxia on Monday, May 18, 2026
CARLSBAD, Calif., May 17, 2026 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, wil...
Design Therapeutics initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald initiated coverage of Design Therapeutics (DSGN) with an Overweight rating. The firm expects DT-216P2, the company’s lead asset which is designed to elicit improvements in endogenous...
Design Therapeutics initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald initiated coverage of Design Therapeutics (DSGN) with an Overweight rating with no price target
Design Therapeutics price target raised to $21 from $18 at Oppenheimer
Oppenheimer raised the firm’s price target on Design Therapeutics (DSGN) to $21 from $18 and keeps an Outperform rating on the shares. The firm hosted management to discuss the recent…
Design Therapeutics price target raised to $20 from $12 at Piper Sandler
Piper Sandler raised the firm’s price target on Design Therapeutics (DSGN) to $20 from $12 and keeps an Overweight rating on the shares. The firm caught up with management following…
Design Therapeutics reports Q1 EPS (29c), consensus (33c)
“The first quarter was marked by continued operational execution across our portfolio as we progress our clinical programs, including our ongoing RESTORE-FA multiple ascending dose trial evaluating DT...
Design Therapeutics Announces First Quarter 2026 Financial Results and Recent Business Updates
Additional Detail Provided for RESTORE-FA (DT-216P2) Trial Design, Dosing and Endpoints David Shapiro, M.D., Appointed to Board of Directors, Strengthening Clinical and Regulatory Expertise Cash and S...
Design Therapeutics Earnings Call Transcript: Q1 2026
RESTORE-FA, a multiple ascending dose trial for FA, is progressing well with interim data expected later this year. The study focuses on DT-216's ability to increase frataxin levels, aiming to establish a regulatory path using biomarker endpoints.